PortfoliosLab logoPortfoliosLab logo
APLS vs. ULTA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

APLS vs. ULTA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Apellis Pharmaceuticals, Inc. (APLS) and Ulta Beauty, Inc. (ULTA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, APLS achieves a 63.34% return, which is significantly higher than ULTA's -22.12% return.


APLS

1D
0.00%
1M
0.15%
YTD
63.34%
6M
93.08%
1Y
118.01%
3Y*
-22.49%
5Y*
-1.50%
10Y*

ULTA

1D
-4.78%
1M
-9.03%
YTD
-22.12%
6M
-13.46%
1Y
-0.40%
3Y*
3.71%
5Y*
7.61%
10Y*
7.13%
*Multi-year figures are annualized to reflect compound growth (CAGR)

APLS vs. ULTA - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
APLS
Apellis Pharmaceuticals, Inc.
63.34%-21.28%-46.69%15.76%9.37%-17.34%86.81%132.15%-39.22%54.67%
ULTA
Ulta Beauty, Inc.
-22.12%39.11%-11.24%4.46%13.76%43.59%13.44%3.39%9.47%12.28%

Correlation

The correlation between APLS and ULTA is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.13

Correlation (3Y)
Calculated over the trailing 3-year period

0.15

Correlation (5Y)
Calculated over the trailing 5-year period

0.20

Correlation (All Time)
Calculated using the full available price history since Nov 10, 2017

0.19

Fundamentals

EPS

APLS:

$1.41

ULTA:

$26.57

PE Ratio

APLS:

29.10

ULTA:

17.73

PS Ratio

APLS:

3.77

ULTA:

1.66

Total Revenue (TTM)

APLS:

$1.03B

ULTA:

$12.71B

Gross Profit (TTM)

APLS:

$920.13M

ULTA:

$5.00B

EBITDA (TTM)

APLS:

$176.85M

ULTA:

$1.81B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

APLS vs. ULTA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

APLS
APLS Risk / Return Rank: 8585
Overall Rank
APLS Sharpe Ratio Rank: 7171
Sharpe Ratio Rank
APLS Sortino Ratio Rank: 9393
Sortino Ratio Rank
APLS Omega Ratio Rank: 9595
Omega Ratio Rank
APLS Calmar Ratio Rank: 8484
Calmar Ratio Rank
APLS Martin Ratio Rank: 8282
Martin Ratio Rank

ULTA
ULTA Risk / Return Rank: 3737
Overall Rank
ULTA Sharpe Ratio Rank: 4040
Sharpe Ratio Rank
ULTA Sortino Ratio Rank: 3434
Sortino Ratio Rank
ULTA Omega Ratio Rank: 3434
Omega Ratio Rank
ULTA Calmar Ratio Rank: 4040
Calmar Ratio Rank
ULTA Martin Ratio Rank: 3939
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

APLS vs. ULTA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Apellis Pharmaceuticals, Inc. (APLS) and Ulta Beauty, Inc. (ULTA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


APLSULTADifference

Sharpe ratio

Return per unit of total volatility

0.99

-0.01

+1.00

Sortino ratio

Return per unit of downside risk

3.67

0.22

+3.45

Omega ratio

Gain probability vs. loss probability

1.58

1.03

+0.55

Calmar ratio

Return relative to maximum drawdown

3.37

-0.01

+3.38

Martin ratio

Return relative to average drawdown

7.45

-0.03

+7.48

APLS vs. ULTA - Sharpe Ratio Comparison

The current APLS Sharpe Ratio is 0.99, which is higher than the ULTA Sharpe Ratio of -0.01. The chart below compares the historical Sharpe Ratios of APLS and ULTA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


APLSULTADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.99

-0.01

+1.00

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.02

0.22

-0.24

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.19

Sharpe Ratio (All Time)

Calculated using the full available price history

0.16

0.35

-0.19

Drawdowns

APLS vs. ULTA - Drawdown Comparison

The maximum APLS drawdown since its inception was -82.47%, smaller than the maximum ULTA drawdown of -87.89%. Use the drawdown chart below to compare losses from any high point for APLS and ULTA.


Loading charts...

Drawdown Indicators


APLSULTADifference

Max Drawdown

Largest peak-to-trough decline

-82.47%

-87.89%

+5.42%

Max Drawdown (1Y)

Largest decline over 1 year

-43.53%

-33.33%

-10.20%

Max Drawdown (3Y)

Largest decline over 3 years

-82.47%

-44.56%

-37.91%

Max Drawdown (5Y)

Largest decline over 5 years

-82.47%

-44.56%

-37.91%

Max Drawdown (10Y)

Largest decline over 10 years

-64.92%

Current Drawdown

Current decline from peak

-56.03%

-33.33%

-22.70%

Average Drawdown

Average peak-to-trough decline

-37.13%

-20.79%

-16.34%

Ulcer Index

Depth and duration of drawdowns from previous peaks

19.63%

12.98%

+6.65%

Volatility

APLS vs. ULTA - Volatility Comparison

The current volatility for Apellis Pharmaceuticals, Inc. (APLS) is 0.54%, while Ulta Beauty, Inc. (ULTA) has a volatility of 9.57%. This indicates that APLS experiences smaller price fluctuations and is considered to be less risky than ULTA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


APLSULTADifference

Volatility (1M)

Calculated over the trailing 1-month period

0.54%

9.57%

-9.03%

Volatility (6M)

Calculated over the trailing 6-month period

91.44%

27.65%

+63.79%

Volatility (1Y)

Calculated over the trailing 1-year period

147.98%

33.15%

+114.83%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

91.01%

34.28%

+56.73%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

83.60%

38.30%

+45.30%

Dividends

APLS vs. ULTA - Dividend Comparison

Neither APLS nor ULTA has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

APLS vs. ULTA - Financials Comparison

This section allows you to compare key financial metrics between Apellis Pharmaceuticals, Inc. and Ulta Beauty, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.001.00B2.00B3.00B4.00B20222023202420252026
192.01M
3.16B
(APLS) Total Revenue
(ULTA) Total Revenue
Values in USD except per share items

APLS vs. ULTA - Profitability Comparison

The chart below illustrates the profitability comparison between Apellis Pharmaceuticals, Inc. and Ulta Beauty, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

40.0%50.0%60.0%70.0%80.0%90.0%100.0%20222023202420252026
78.9%
40.1%
Portfolio components
APLS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Apellis Pharmaceuticals, Inc. reported a gross profit of 151.46M and revenue of 192.01M. Therefore, the gross margin over that period was 78.9%.

ULTA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Ulta Beauty, Inc. reported a gross profit of 1.27B and revenue of 3.16B. Therefore, the gross margin over that period was 40.1%.

APLS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Apellis Pharmaceuticals, Inc. reported an operating income of 26.47M and revenue of 192.01M, resulting in an operating margin of 13.8%.

ULTA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Ulta Beauty, Inc. reported an operating income of 448.26M and revenue of 3.16B, resulting in an operating margin of 14.2%.

APLS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Apellis Pharmaceuticals, Inc. reported a net income of 18.66M and revenue of 192.01M, resulting in a net margin of 9.7%.

ULTA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Ulta Beauty, Inc. reported a net income of 340.47M and revenue of 3.16B, resulting in a net margin of 10.8%.


Frequently Asked Questions


APLS and ULTA have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ULTA has higher volatility (9.57%) compared to APLS (0.54%). In terms of maximum drawdown, APLS dropped -82.47% vs ULTA's -87.89%.

APLS currently has the higher Sharpe Ratio (0.99 vs -0.01), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for APLS and ULTA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer